PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study

BACKGROUND: PD‐1 inhibitors are routinely used for the treatment of advanced melanoma. This study sought to determine whether PD‐L1 expression on circulating tumor cells (CTCs) can serve as a predictive biomarker of clinical benefit and response to treatment with the PD‐1 inhibitor pembrolizumab. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Khattak, Muhammad A., Reid, Anna, Freeman, James, Pereira, Michelle, McEvoy, Ashleigh, Lo, Johnny, Frank, Markus H., Meniawy, Tarek, Didan, Ali, Spencer, Isaac, Amanuel, Benhur, Millward, Michael, Ziman, Melanie, Gray, Elin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Immuno‐Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066715/
https://www.ncbi.nlm.nih.gov/pubmed/32162809
http://dx.doi.org/10.1634/theoncologist.2019-0557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066715/
https://www.ncbi.nlm.nih.gov/pubmed/32162809
http://dx.doi.org/10.1634/theoncologist.2019-0557

Ejemplares similares